Clinical enrollment focus Acurian is now part of Accelerated Enrollment Solutions (AES), emphasizing end-to-end trial acceleration through combined site and enrollment services. Opportunity: position integrated enrollment optimization offerings to sponsors seeking faster patient recruitment and reduced study timelines.

NAFLD/NASH specialization Recent launches target NAFLD and NASH patient enrollment, signaling a niche specialization in liver disease trial recruitment. Opportunity: approach sponsors and CROs running NAFLD/NASH programs with tailored patient sourcing and retention strategies leveraging Acurian's platform.

Crohn’s and colitis app Introduction of COLO app for symptom tracking in Crohn’s disease and ulcerative colitis expands digital patient engagement capabilities. Opportunity: offer digital health tools and real-time patient data to improve retention, endpoints quality, and trial adherence for gastroenterology studies.

Strategic partnerships Historically active with Synexus and site-network collaborations, including SynexusPlus and joint NAFLD/NASH initiatives. Opportunity: explore co-sponsorship or joint enrollment programs with site networks to scale patient recruitment across regions with shared risk and reward models.

Mid-market growth potential Revenue range ($10M-$25M) and a mid-sized employee base (201-500) position Acurian to target mid-market pharma and specialty biotech sponsors that need flexible, fast-turnaround enrollment solutions without the scale of mega-CROs. Opportunity: tailor scalable enrollment packages, price bands, and service levels for growing sponsors seeking efficient, predictable study timelines.